{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:52:30Z","timestamp":1792723950876,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jval.2016.08.724","type":"journal-article","created":{"date-parts":[[2016,10,9]],"date-time":"2016-10-09T11:45:10Z","timestamp":1476013510000},"page":"132-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States"],"prefix":"10.1016","volume":"20","author":[{"given":"Kevin","family":"Marsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Zaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Orfanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Salverda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailja","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2016.08.724_bib1","series-title":"Factors influencing satisfaction with COPD maintenance","author":"Mocarski","year":"2011"},{"key":"10.1016\/j.jval.2016.08.724_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1378\/chest.11-0406","article-title":"Efficacy of aclidinium bromide 400 \u00b5g twice daily compared with placebo and tiotropium in patients with moderate to severe COPD","volume":"141","author":"Fuhr","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jval.2016.08.724_bib3","series-title":"Multiple Criteria Decision Analysis: An Integrated Approach","author":"Belton","year":"2002"},{"key":"10.1016\/j.jval.2016.08.724_bib4","series-title":"Multi-Criteria Analysis: A Manual","year":"2009"},{"key":"10.1016\/j.jval.2016.08.724_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1478-7547-4-14","article-title":"Priority setting of health interventions: the need for multi-criteria decision analysis","volume":"4","author":"Baltussen","year":"2006","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.jval.2016.08.724_bib6","series-title":"Incorporating Multiple Criteria in HTA: Methods and Processes","author":"Devlin","year":"2011"},{"key":"10.1016\/j.jval.2016.08.724_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40273-014-0135-0","article-title":"Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature","volume":"32","author":"Marsh","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2016.08.724_bib8","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jval.2012.06.015","article-title":"Multiple criteria decision analysis for health technology assessment","volume":"15","author":"Thokala","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2016.08.724_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/pds.3636","article-title":"Balancing benefit and risk of medicines: a systematic review and classification of available methodologies","volume":"23","author":"Mt-Isa","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2016.08.724_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.pec.2008.07.032","article-title":"Shared decision-making\u2014transferring research into practice: the Analytic Hierarchy Process (AHP)","volume":"73","author":"Dolan","year":"2008","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.jval.2016.08.724_bib11","unstructured":"Chronic Obstructive Pulmonary Disorder (COPD)\u2014KOL Insight and Consensus Outlook. October 2013. Available from: http:\/\/www.researchandmarkets.com\/reports\/2686120\/chronic_obstructive_pulmonary_disorder_copd. [Accessed September 12, 2016]"},{"key":"10.1016\/j.jval.2016.08.724_bib12","doi-asserted-by":"crossref","first-page":"29s","DOI":"10.1183\/09031936.03.00078203","article-title":"The burden of illness and economic evaluation for COPD","volume":"41","author":"Ramsey","year":"2003","journal-title":"Eur Respir J Suppl"},{"key":"10.1016\/j.jval.2016.08.724_bib13","unstructured":"Kaplan, W. Background Paper 6.13 Chronic Obstructive Pulmonary Disease (COPD). 2013. Available from: http:\/\/www.who.int\/medicines\/areas\/priority_medicines\/BP6_13COPD.pdf. [Accessed September 12, 2016]."},{"key":"10.1016\/j.jval.2016.08.724_bib14","year":"2012","journal-title":"FDA approves Tudorza Pressair to treat chronic obstructive pulmonary disease"},{"key":"10.1016\/j.jval.2016.08.724_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/1753465812463626","article-title":"The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease","volume":"6","author":"Maltais","year":"2012","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jval.2016.08.724_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","article-title":"The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jval.2016.08.724_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4104\/pcrj.2011.00102","article-title":"Beyond lung function in COPD management: effectiveness of LABA\/LAMA combination therapy on patient-centred outcomes","volume":"21","author":"van der Molen","year":"2012","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.jval.2016.08.724_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/15412555.2013.814626","article-title":"Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study","volume":"10","author":"Beier","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.jval.2016.08.724_bib19","series-title":"Improvement in COPD Symptoms with Aclidinium Bromide Compared with Placebo and Tiotropium: A Phase IIIb Study PPT","author":"Beier","year":"2013"},{"key":"10.1016\/j.jval.2016.08.724_bib20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1378\/chest.130.6.1695","article-title":"Pooled clinical trial analysis of tiotropium safety","volume":"130","author":"Kesten","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jval.2016.08.724_bib21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","article-title":"Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Singh","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2016.08.724_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/COPD.S4802","article-title":"Tiotropium HandiHaler\u00ae in the treatment of COPD: a safety review","volume":"4","author":"Kesten","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jval.2016.08.724_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1183\/09031936.06.00062705","article-title":"The effect of tiotropium on exacerbations and airflow in patients with COPD","volume":"27","author":"Dusser","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2016.08.724_bib24","unstructured":"Food and Drug Administration. Patient preference information\u2014submission, review in PMAs, HDE applications, and de novo requests, and inclusion in device labeling: draft guidance for industry, Food and Drug Administration staff, and other stakeholders. 2015. Available from: http:\/\/www.fda.gov\/downloads\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm446680.pdf. [Accessed April 5, 2016]."},{"key":"10.1016\/j.jval.2016.08.724_bib25","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1007\/s00464-014-4044-2","article-title":"Incorporating patient-preference evidence into regulatory decision making","volume":"29","author":"Ho","year":"2015","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jval.2016.08.724_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1377\/hlthaff.2011.0003","article-title":"Informing and involving patients to improve the quality of medical decisions","volume":"30","author":"Fowler","year":"2011","journal-title":"Health Aff"},{"key":"10.1016\/j.jval.2016.08.724_bib27","first-page":"386","article-title":"Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer","volume":"7","author":"daCosta DiBonaventura","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jval.2016.08.724_bib28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/17425247.2013.808186","article-title":"Preference, satisfaction and errors with two dry powder inhalers in patients with COPD","volume":"10","author":"van der Palen","year":"2013","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jval.2016.08.724_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1524-4733.2010.00725.x","article-title":"A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy\u2014report of the ISPOR Risk-Benefit Management Working Group","volume":"13","author":"Guo","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2016.08.724_bib30","article-title":"Recommendations for the Methodology and Visualisation Techniques to Be Used in the Assessment of Benefit and Risk of Medicines. IMI-PROTECT Benefit-Risk Group Recommendations Report","author":"Hughes","year":"2013","journal-title":"IMI-PROTECT Benefit-Risk Group"},{"key":"10.1016\/j.jval.2016.08.724_bib31","author":"Mt-Isa","year":"2013","journal-title":"Review of methodologies for benefit and risk assessment of medication. IMI PROTECT WP5"},{"key":"10.1016\/j.jval.2016.08.724_bib32","unstructured":"Keeney RL, von Winterfeldt D. Practical value models. Published articles and papers. Paper 36. 2009. Available from: http:\/\/research.create.usc.edu\/published_papers\/36. [Accessed April 5, 2016]."},{"key":"10.1016\/j.jval.2016.08.724_bib33","series-title":"Patients\u2019 experience of nighttime symptoms: results from qualitative research","author":"Schaefer","year":"2011"},{"key":"10.1016\/j.jval.2016.08.724_bib34","series-title":"Nighttime symptoms of COPD and associated reductions in quality of life in a clinical trial population","author":"Mocarski","year":"2012"},{"key":"10.1016\/j.jval.2016.08.724_bib35","series-title":"Healthcare resource utilization among COPD patients with nighttime and early morning symptoms","author":"Sullivan","year":"2013"},{"key":"10.1016\/j.jval.2016.08.724_bib36","year":"2010"},{"key":"10.1016\/j.jval.2016.08.724_bib37","year":"2012"},{"key":"10.1016\/j.jval.2016.08.724_bib38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S48967","article-title":"Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis","volume":"8","author":"Karabis","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jval.2016.08.724_bib39","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00225511","article-title":"Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study","volume":"40","author":"Jones","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2016.08.724_bib40","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2016.08.724_bib41","series-title":"New drug evaluation: aclidinium bromide","author":"Fouts","year":"2013"},{"key":"10.1016\/j.jval.2016.08.724_bib42","series-title":"Economic evaluation of aclidinium bromide in the management of moderate to severe COPD","author":"Karabis","year":"2013"},{"key":"10.1016\/j.jval.2016.08.724_bib43","series-title":"Preferred Drug List Illinois Medicaid","year":"2013"},{"key":"10.1016\/j.jval.2016.08.724_bib44","series-title":"PDL New Drug Review, Proprietary Name","year":"2013"},{"key":"10.1016\/j.jval.2016.08.724_bib45","series-title":"Mississippi Division of Medicaid. Mississippi Division of Medicaid Preferred Drug List Changes","year":"2013"},{"key":"10.1016\/j.jval.2016.08.724_bib46","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/0272989X15587005","article-title":"Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention","volume":"35","author":"Tervonen","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2016.08.724_bib47","doi-asserted-by":"crossref","DOI":"10.1287\/opre.50.6.935.357","article-title":"Common mistakes in making value trade-offs","volume":"50","author":"Keeney","year":"2002","journal-title":"Oper Res"},{"key":"10.1016\/j.jval.2016.08.724_bib48","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/risa.12360","article-title":"Cognitive and motivational biases in decision and risk analysis","volume":"35","author":"Montibeller","year":"2015","journal-title":"Risk Anal"},{"key":"10.1016\/j.jval.2016.08.724_bib49","unstructured":"Marsh K, Thokala P, M\u00fchlbacher A, Lanitis T. Incorporating preferences and priorities into MCDA: selecting an appropriate scoring and weighting technique. In: Marsh K, Thokala P, Goetghebeur M, Baltussen B, eds., Healthcare Decisions Supported by Multi-Criteria Decision Analysis. New York: Springer, In Press."}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301516313043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301516313043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T16:25:09Z","timestamp":1536337509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301516313043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1098301516313043"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2016.08.724","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2016.08.724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}